US drugmaker Amgen to invest $200 million in India

US biopharmaceutical firm Amgen on Monday announced an initial investment of $200 million in its newly inaugurated technology and innovation center in Hyderabad, with plans for further investments in the coming years.

Amgen chief executive officer Robert Bradway made the announcement at the center’s inauguration, which was also attended by Telangana chief minister Revanth Reddy.

Amgen is investing “an initial $200 million in this center” during 2025, “and we plan to make additional significant investments in future years,” Reuters reported Bradway as saying.

The center will use artificial intelligence (AI) and data science to help create new medicines. By the end of the year, the center will have about 2,000 employees, up from around 300 now, said Som Chattopadhyay, national executive for India at Amgen, the Press Trust of India reported.

Meanwhile, chief minister Reddy said Telangana aims to become a $1 trillion economy and a leader in the global pharmaceutical and biotechnology industries.

Reddy didn’t give a timeline, but said his state is working to become a new center for manufacturing and research as part of the “China Plus One” strategy, which helps businesses expand beyond China.

“We are committed to your success, your growth, and your long-term vision. I request you to invest in research collaborations, skill development programs, and academic partnerships,” Reddy told Amgen’s boss.

The inauguration comes ahead of the BioAsia conference in Hyderabad this week, where executives from global pharmaceutical companies, including Amgen, Eli Lilly, and Novartis, as well as leading Indian pharmaceutical firms, will participate.

India’s pharmaceutical industry has been attracting major global companies. However, there may be problems ahead as the Donald Trump administration is considering adding high taxes (25% or more) on medicine imports. This could affect Indian companies that make generic drugs given that the US. is India’s biggest market.